進行固形腫瘍におけるPHST001の研究
進行した再発および/または難治性固形腫瘍を有する成人患者におけるPHST001の安全性、薬物動態、薬力学、および抗腫瘍活性を調査した、開いた盲検1A/1B、用量エスカレーションおよび用量拡大研究
This is a multi-center, first-in-human (FIH), open-label, Phase 1a/1b dose escalation and dose expansion study to assess the safety, PK, pharmacodynamics, and antitumor activity of PHST001 monotherapy (Phase 1a) or in combination with anticancer therapies (Phase 1b) in adult participants with advanced relapsed and/or refractory solid tumors (including but not limited to CNS tumors in Phase 1a only). Phase 1b will include the following cohorts 1) tumor-specific cohorts for participants with advanced relapsed and/or refractory ovarian cancer, endometrial cancer, and cholangiocarcinoma, 2) a randomized cohort for participants with ovarian cancer who will receive PHST001 in combination with mirvetuximab soravtansine, 3) a cohort for participants with advanced/metastatic breast cancer who will receive PHST001 in combination with trastuzumab deruxtecan and 4) a cohort of patients who consent to additional biomarker studies.
The study's primary objectives are to evaluate the safety and tolerability of PHST001 and determine the RP2D (Recommended Phase 2 dose) of PHST001 as monotherapy and in combination with anticancer therapies, as well as to assess the anti-tumor activity of PHST001 in combination with anticancer therapies in Phase 1b.
調査の概要
状態
研究の種類
入学 (推定)
段階
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:Raphaël Rousseau, Chief Medical Officer, PhD, MD
- 電話番号:650-260-8443
- メール:medical@pheast.com
研究場所
-
-
California
-
Beverly Hills、California、アメリカ、90212
- 募集
- Precision NextGen Oncology & Research Center
-
コンタクト:
- Jing Liu
- 電話番号:424-777-0708
- メール:JingL@nextgenonc.com, research@nextgenonc.com
-
主任研究者:
- Kamlesh Kumar Sankhala, MD
-
Los Angeles、California、アメリカ、90033
- 募集
- USC Norris Comprehensive Cancer Center
-
コンタクト:
- Lorraine Martinez
- メール:Lorraine.Martinez@med.usc.edu
-
コンタクト:
- Stephanie Kim
- メール:Stephanie.Kim2@med.usc.edu
-
Palo Alto、California、アメリカ、94304
- 募集
- Stanford University School of Medicine
-
コンタクト:
- Kayla McDaniel
- 電話番号:650-498-7293
- メール:mcda59@stanford.edu
-
主任研究者:
- Oliver Dorigo, MD, PhD
-
-
Colorado
-
Denver、Colorado、アメリカ、80218
- 募集
- Sarah Cannon Research Institute (SCRI) Oncology Partners - Denver Health One
-
コンタクト:
- Sarah Cannon Research Institute at HCA HealthONE
- 電話番号:720-754-2610
- メール:CANN.DDUDenverGeneral@SarahCannon.com
-
-
Connecticut
-
New Haven、Connecticut、アメリカ、06520
- 募集
- Yale Cancer Center
-
主任研究者:
- Michael Cecchini, MD
-
コンタクト:
- Priscilla Stéve
- 電話番号:203-464-5564
- メール:Priscilla.steve@yale.edu
-
-
Illinois
-
Chicago、Illinois、アメリカ、60637
- 募集
- University of Chicago Medical Center
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02215
- 募集
- Dana Farber Cancer Institute
-
主任研究者:
- Michael Dennis, MD
-
コンタクト:
- DFCI CCTI Referrals
- メール:dfcicctiexternalreferral@dfci.harvard.edu
-
-
Michigan
-
Ann Arbor、Michigan、アメリカ、48109
- 募集
- University of Michigan Rogel Cancer Center
-
主任研究者:
- Ulka Vaishampayan, MD
-
コンタクト:
- University of Michigan Health Cancer AnswerLine
- 電話番号:1-800-865-1125
- メール:canceranswerline@med.umich.edu
-
Grand Rapids、Michigan、アメリカ、49546
- 募集
- START Center for Cancer Research - Midwest
-
主任研究者:
- Sreenivasa Chandana, MD, PhD
-
コンタクト:
- START HOPE Team
- メール:hopeteam@startresearch.com
-
-
New York
-
Lake Success、New York、アメリカ、11042
- 募集
- START Center for Cancer Research - Long Island New York
-
主任研究者:
- Geraldine O'Sullivan Coyne, MD
-
コンタクト:
- Sadia Morium
- 電話番号:363-207-5166
- メール:sadia.morium@startresearch.com
-
New York、New York、アメリカ、10029
- 募集
- Mount Sinai
-
主任研究者:
- Thomas Marron, MD, PhD
-
コンタクト:
- Jordan Cuevas
- 電話番号:212-824-7945
- メール:jordan.cuevas@mssm.edu
-
-
North Carolina
-
Durham、North Carolina、アメリカ、27710
- 募集
- Duke Cancer Institute
-
コンタクト:
- Phase 1 and Immunotherapy Team
- 電話番号:919-684-6342
- メール:Phase1andImmunotherapyreferrals@duke.edu
-
主任研究者:
- Niharika Mettu, MD, PhD
-
-
Tennessee
-
Nashville、Tennessee、アメリカ、37203
- 募集
- Vanderbilt-Ingram Cancer Center
-
コンタクト:
- Clinical Trials Office (CTO)
- 電話番号:1-800-811-8480
- メール:cip@vumc.org
-
主任研究者:
- Elizabeth Davis, MD, PhD
-
Nashville、Tennessee、アメリカ、37203
- 募集
- Sarah Cannon Research Institute (SCRI) Oncology Partners
-
主任研究者:
- Deepak Bhamidipati, MD
-
コンタクト:
- SCRI Oncology Partners - Nashville
- 電話番号:1-877-MY-1-SCRI (691-7274)
- メール:ASKSARAH@scresearch.net
-
-
Texas
-
Fort Worth、Texas、アメリカ、76104
- 募集
- START Center for Cancer Research - Texas
-
コンタクト:
- START HOPE Team
- メール:hopeteam@startresearch.com
-
主任研究者:
- Henry Xiong, MD, PhD
-
Houston、Texas、アメリカ、77030
- 募集
- MD Anderson Cancer Center
-
コンタクト:
- MD Anderson Cancer Center
- 電話番号:713-563-1930
- メール:ICTNPCS@mdanderson.org
-
主任研究者:
- Stéphane Champiat, MD, PhD
-
Irving、Texas、アメリカ、75039
- 募集
- NEXT Oncology - Dallas
-
主任研究者:
- Michael Song, MD, PhD, PharmD
-
コンタクト:
- NEXT Referrals-Dallas
- 電話番号:fax: 210-568-4577
- メール:nxt_txreferrals@nextoncology.com
-
San Antonio、Texas、アメリカ、78229
- 募集
- University of Texas (UT) Health
-
主任研究者:
- Daruka Mahadevan, MD, PhD
-
コンタクト:
- Mays Cancer Center Research Team
- メール:mccresearch@uthscsa.edu
-
San Antonio、Texas、アメリカ、78229
- 募集
- START Center for Cancer Research - San Antonio
-
主任研究者:
- Kyriakos Papadopoulos, MD
-
コンタクト:
- START HOPE Team
- 電話番号:210-593-5250
- メール:hopeteam@startresearch.com
-
-
Virginia
-
Fairfax、Virginia、アメリカ、22031
- 募集
- NEXT Oncology - Virginia
-
コンタクト:
- Carrie Friedman
- メール:adelgado@nextoncology.com
-
コンタクト:
- Allison Delgado
- メール:carrie.friedman@usoncology.com
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Key Inclusion Criteria:
- Histologically or cytologically confirmed advanced solid tumor which has relapsed from or been refractory to all locally available standard therapies.
- Adequate organ function per laboratory testing
- Pregnancy prevention requirements
- Measurable disease per RECIST v1.1 (or RANO) as assessed by the local site Investigator/radiology
- Performance status of 0 or 1 on Eastern Cooperative Oncology Group (ECOG) scale
Key Exclusion Criteria:
- Diagnosis of immunodeficiency
- History of a previous additional malignancy, unless potentially curative treatment has been completed, with no evidence of malignancy for 2 years. Participants with basal cell carcinoma of the skin, Stage I melanoma, melanoma in situ, squamous cell carcinoma of the skin, early-stage prostate cancer, low grade neoplasms, or carcinoma in situ, excluding carcinoma in situ of the bladder, who have undergone potentially curative therapy are not excluded and can be enrolled regardless of disease-free period following completion of potentially curative therapy. Participants with early-stage breast cancer who have undergone curative intent treatment and with no disease recurrence for 2 years after treatment are not excluded.
- Active known CNS metastases and/or carcinomatous meningitis from a systemic (non-CNS) primary malignancy. Participants with previously treated CNS metastases are eligible, provided they are radiologically and clinically stable (i.e., no evidence of progression for at least 2 weeks by repeat imaging performed during screening) and are not requiring systemic corticosteroids above the physiologic replacement for at least 7 days prior to the first dose of study treatment.
- Received prior systemic anticancer therapy including investigational agents within 21 days or, if shorter, within 5 half-lives prior to the first dose of study treatment. Participants must have recovered from all AEs due to previous therapies to Grade ≤1 or baseline. Participants with Grade ≤2 neuropathy may be eligible. Participants with endocrine-related AEs Grade ≤2 requiring treatment or hormone replacement may be eligible.
- Prior autologous or allogeneic hematopoietic stem cell transplant or solid organ transplant.
- Received previous treatment with another agent targeting CD24.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:順次割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:PHST001 Monotherapy
Participants will receive PHST001 monotherapy administered once every 3 weeks (Q3W). In Phase 1a, PHST001 will be evaluated in sequential dose-escalation cohorts at planned dose levels of 0.1, 0.3, 1.0, 2.0, 4.0, 6.0, 9.0, 18.0, and 36.0 mg/kg. Dose levels may be modified or additional dose levels evaluated based on emerging safety, pharmacokinetic, pharmacodynamic, and antitumor activity data. Participants in the Phase 1b biomarker cohort may also receive PHST001 monotherapy. |
PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals. |
|
実験的:PHST001 + Paclitaxel
Participants will receive PHST001 in combination with paclitaxel. The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in tumor-specific expansion cohorts, including participants with ovarian carcinoma, endometrial carcinoma, or cholangiocarcinoma, and/or in the biomarker cohort. |
PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals. Paclitaxel used as per standard of care.
他の名前:
|
|
実験的:PHST001 + Topotecan
Participants will receive PHST001 in combination with topotecan. The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in the ovarian carcinoma expansion cohort and/or biomarker cohort. |
PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals. Topotecan used as per standard of care.
他の名前:
|
|
実験的:PHST001 + Doxorubicin
Participants will receive PHST001 in combination with doxorubicin. The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in ovarian carcinoma or endometrial carcinoma expansion cohorts and/or the biomarker cohort. |
PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals. Doxorubicin used as per standard of care.
他の名前:
|
|
実験的:PHST001 + FOLFIRI
Participants will receive PHST001 in combination with FOLFIRI (5-fluorouracil, folinic acid, and irinotecan). The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in the cholangiocarcinoma expansion cohort and/or biomarker cohort. |
PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals. FOLFIRI used as per standard of care.
他の名前:
|
|
実験的:PHST001 + FOLFOX
Participants will receive PHST001 in combination with FOLFOX (5-fluorouracil, folinic acid, and oxaliplatin). The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in the cholangiocarcinoma expansion cohort and/or biomarker cohort. |
PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals. FOLFOX used as per standard of care.
他の名前:
|
|
実験的:PHST001 + Gemcitabine
Participants will receive PHST001 in combination with gemcitabine. The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in ovarian carcinoma or cholangiocarcinoma expansion cohorts and/or the biomarker cohort. |
PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals. Gemcitabine used as per standard of care.
他の名前:
|
|
実験的:PHST001 + Mirvetuximab Soravtansine
Participants will receive PHST001 in combination with mirvetuximab soravtansine. The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in the ovarian carcinoma expansion cohort and/or in the biomarker cohort. Half of the participants in the randomized ovarian carcinoma cohort may be randomly assigned to receive PHST001 in combination with mirvetuximab soravtansine. |
PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals. Mirvetuximab soravtansine used as per standard of care.
他の名前:
|
|
実験的:PHST001 + Trastuzumab Deruxtecan
Participants will receive PHST001 in combination with trastuzumab deruxtecan. The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in participants with advanced or metastatic breast cancer and/or in the biomarker cohort. |
PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals. Trastuzumab deruxtecan used as per standard of care.
他の名前:
|
|
アクティブコンパレータ:Mirvetuximab Soravtansine Monotherapy
Participants with ovarian carcinoma enrolled in the randomized Phase 1b expansion cohort will be randomized 1:1 to receive mirvetuximab soravtansine monotherapy or mirvetuximab soravtansine in combination with PHST001. Participants assigned to this arm will receive mirvetuximab soravtansine monotherapy. |
Mirvetuximab soravtansine used as per standard of care.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Frequency of Dose-Limiting Toxicities (DLTs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
時間枠:From first dose of PHST001 through 21 days after the first dose of PHST001
|
Based on toxicities observed |
From first dose of PHST001 through 21 days after the first dose of PHST001
|
|
Frequency of Serious Adverse Events (SAEs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
時間枠:From signed consent up to 90 days after the last dose of PHST001
|
Based on toxicities observed |
From signed consent up to 90 days after the last dose of PHST001
|
|
Frequency of Treatment Emergent Adverse Events (TEAEs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
時間枠:From first dose up to 90 days after the last dose of PHST001
|
Based on toxicities observed |
From first dose up to 90 days after the last dose of PHST001
|
|
Frequency of Treatment Related Adverse Events (TRAEs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
時間枠:From first dose up to 90 days after the last dose of PHST001
|
Based on toxicities observed |
From first dose up to 90 days after the last dose of PHST001
|
|
Frequency of Adverse Events of Special Interest (AESIs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
時間枠:From first dose up to 90 days after the last dose of PHST001
|
Based on toxicities observed |
From first dose up to 90 days after the last dose of PHST001
|
|
Frequency of AEs Leading to Dose Interruption or Treatment Discontinuation and AEs Leading to Death to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
時間枠:From first dose up to 90 days after the last dose of PHST001
|
Based on toxicities observed |
From first dose up to 90 days after the last dose of PHST001
|
|
Overall Response Rate (ORR) based on RECIST v1.1 to assess the preliminary antitumor activity of PHST001 in combination with anticancer therapy (Phase 1b non-randomized cohorts only)
時間枠:From screening and during treatment up to 2 years
|
Defined as the proportion of subjects with confirmed complete response (CR) or partial response (PR); a confirmed response is a response that persists on repeat-imaging ≥ 4 weeks after initial documentation of response. |
From screening and during treatment up to 2 years
|
|
Progression-Free Survival (PFS) based on RECIST v1.1 to assess the preliminary antitumor activity of PHST001 in combination with anticancer therapy (Phase 1b randomized cohort only)
時間枠:From screening and during treatment up to 2 years
|
Defined as the time from first dose of PHST001 to first documentation of radiographic disease progression or death, whichever occurs first. |
From screening and during treatment up to 2 years
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Overall Response Rate (ORR) based on RECIST v1.1 (or RANO for primary CNS Tumors) to assess the preliminary antitumor activity of PHST001 as monotherapy (Phase 1a) and in combination with anticancer therapy (Phase 1b - randomized cohort only)
時間枠:From screening and during treatment up to 2 years
|
Defined as the proportion of subjects with confirmed complete response (CR) or partial response (PR); a confirmed response is a response that persists on repeat-imaging ≥ 4 weeks after initial documentation of response. |
From screening and during treatment up to 2 years
|
|
Duration of Response (DOR) based on RECIST v1.1 (or RANO for primary CNS Tumors) to assess the preliminary antitumor activity of PHST001 as monotherapy (Phase 1a) and in combination with anticancer therapy (Phase 1b)
時間枠:From screening and during treatment up to 2 years
|
Defined as time from date of first objective response (either CR or PR) to first documentation of radiographic disease progression. |
From screening and during treatment up to 2 years
|
|
Best Overall Response (BOR) based on RECIST v1.1 (or RANO for primary CNS Tumors) to assess the preliminary antitumor activity of PHST001 as monotherapy (Phase 1a) and in combination with anticancer therapy (Phase 1b)
時間枠:From screening and during treatment up to 2 years
|
Defined as the best response recorded for a participant across all time-point assessments from the start of treatment until disease progression or end of treatment. |
From screening and during treatment up to 2 years
|
|
Progression-Free Survival (PFS) based on RECIST v1.1 (or RANO for primary CNS Tumors) to assess the preliminary antitumor activity of PHST001 as monotherapy (Phase 1a) and in combination with anticancer therapy (Phase 1b - non-randomized cohorts only) .
時間枠:From screening and during treatment up to 2 years
|
Defined as the time from first dose of PHST001 to first documentation of radiographic disease progression or death, whichever occurs first. |
From screening and during treatment up to 2 years
|
|
Overall Survival (OS) based on RECIST v1.1 (or RANO for primary CNS Tumors) to assess the preliminary antitumor activity of PHST001 as monotherapy (Phase 1a) and in combination with anticancer therapy (Phase 1b).
時間枠:From screening and during treatment up to 2 years
|
Defined as the time from first dose of PHST001 to the date of death. |
From screening and during treatment up to 2 years
|
|
Maximum Observed Concentration (Cmax) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b).
時間枠:From treatment until 90 days after last dose of PHST001
|
Defined as the maximum blood concentration of a dose of PHST001 |
From treatment until 90 days after last dose of PHST001
|
|
Time to Maximum Concentration (tmax) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
時間枠:From treatment until 90 days after last dose of PHST001
|
Defined as the time required for a dose of PHST001 to reach its maximum blood concentration (Cmax) after administration. |
From treatment until 90 days after last dose of PHST001
|
|
Concentration at the End of a Dosing Interval (Ctrough) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
時間枠:From treatment until 90 days after last dose of PHST001
|
Defined as the blood concentration of a dose of PHST001 at the end of the dosing interval (just prior to next drug administration). |
From treatment until 90 days after last dose of PHST001
|
|
Area Under the Concentration-time Curve (AUC) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
時間枠:From treatment until 90 days after last dose of PHST001
|
Defined as the total PHST001 exposure over time, calculated as the integral of the plasma concentration-time profile. |
From treatment until 90 days after last dose of PHST001
|
|
Volume of Distribution at Steady-state (Vss) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
時間枠:From treatment until 90 days after last dose of PHST001
|
Defined as how widely PHST001 spreads throughout the body once things have stabilized after a dose has been administered. |
From treatment until 90 days after last dose of PHST001
|
|
Clearance (CL) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
時間枠:From treatment until 90 days after last dose of PHST001
|
Defined as the rate at which the body "cleans out" a dose of PHST001 from the bloodstream. |
From treatment until 90 days after last dose of PHST001
|
|
Terminal Elimination Half-life (t½) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
時間枠:From treatment until 90 days after last dose of PHST001
|
Defined as the time it takes for the amount of PHST001 in the body to drop by half during the final phase of elimination. |
From treatment until 90 days after last dose of PHST001
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
- 泌尿生殖器疾患
- 生殖器疾患
- 内分泌系疾患
- 神経系疾患
- 泌尿生殖器腫瘍
- 部位別新生物
- 新生物
- 女性の泌尿生殖器疾患
- 女性の泌尿生殖器疾患と妊娠合併症
- 組織型別の新生物
- 子宮の病気
- 生殖器疾患、女性
- 内分泌腺腫瘍
- 新生物、腺および上皮
- 腺癌
- 卵巣疾患
- 付属器疾患
- 性器腫瘍、女性
- 性腺疾患
- 皮膚疾患
- 乳房の病気
- がん
- 神経系腫瘍
- 子宮腫瘍
- 肉腫
- 新生物、結合組織および軟部組織
- 複合型および混合型の新生物
- 卵管疾患
- 皮膚および結合組織疾患
- 卵巣腫瘍
- 乳房腫瘍
- 胆管癌
- 子宮内膜腫瘍
- 癌肉腫
- 中枢神経系腫瘍
- 卵管腫瘍
- 有機化学物質
- 複素環化化合物、1リング
- 複素環化化合物
- 複素環化化合物、2リング
- 複素環化化合物、融合リング
- 炭化水素
- シクロパラフィン
- 炭化水素、環状
- 炭化水素、周期的
- テルペン
- 炭水化物
- カムプトテシン
- アルカロイド
- 多環芳香族炭化水素
- 炭化水素、芳香
- 多環式化合物
- グリコシド
- 酵素と補酵素
- タキソイド
- シクロデカン
- Diterpenes
- デオキシシチジン
- シチジン
- ピリミジンヌクレオシド
- ピリミジン
- ホルミルテトラヒドロフォレート
- テトラヒドロフォレート
- 葉酸
- 羽毛
- プテリジン
- ウラシル
- ピリミジノン
- アントラサイクリン
- ナフテセン
- アミノグリコシド
- コエンザイム
- ダウノルビシン
- ゲムシタビン
- フルオロウラシル
- ロイコボリン
- ドキソルビシン
- パクリタキセル
- トポテカン
- mirvetuximab soravtansine
- トラスツズマブderuxtecan
- FOLFOXプロトコル
- IFLプロトコル
その他の研究ID番号
- PHST001-101
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。